Mazdutide
also known as IBI362, LY3305677, oxyntomodulin analog
Oxyntomodulin-based dual GLP-1 receptor and glucagon receptor agonist developed by Innovent Biologics in collaboration with Eli Lilly. Phase 3 trials in China demonstrate 12–16% body weight reduction at 24–48 weeks in non-diabetic adults with obesity (BMI ≥30 kg/m²). Once-weekly subcutaneous administration targets dual metabolic pathways — GLP-1-mediated appetite suppression and glucagon-driven energy expenditure.
At a glance
SQ · Abdomen · Once Weekly
Primary target — GLP-1 receptor and glucagon receptor [abdul-2026][elmendorf-2026].
Pathway — Dual agonism: GLP-1R → satiety, insulin secretion, gastric emptying delay; GCGR → hepatic lipolysis, energy expenditure, thermogenesis [elmendorf-2026][abulehia-2026].
Downstream effect — Weight loss via appetite suppression (GLP-1 axis) and increased energy expenditure (glucagon axis); improved glycemic control in T2D.
Origin — Synthetic oxyntomodulin analogue — endogenous peptide with dual GLP-1/glucagon activity.
Feedback intact — Yes — physiological receptor-mediated signaling preserved.
| Parameter | Value |
|---|---|
| Phase 2 studied dose | 9 mg / week [ji-2026]Highest efficacy dose in obesity trial (BMI ≥30 kg/m²). [ji-2026] |
| Frequency | Once weekly [ji-2026][luo-2026] |
| Route | Subcutaneous [ji-2026] |
| Dose escalation | 3 mg → 6 mg → 9 mg (titration schedule in trials)Gradual escalation to minimize GI side effects. |
| Evidence basis | Phase 2 RCT / Phase 3 ongoing [ji-2026][luo-2026] |
| Duration (trials) | 24–48 weeks |
| Population | Non-diabetic adults BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities |
| Phase 3 comparator | Semaglutide 1 mg/week (DREAMS-3 trial) [luo-2026] |
Reconstitution
A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.
Phase 2 RCT (Chinese adults BMI ≥30 kg/m²) · Phase 3 ongoing vs semaglutide · 24–48 weeks [ji-2026][luo-2026]
| Outcome | Finding |
|---|---|
| Percentage body weight loss | 12.4% (pooled meta-analysis, 9 mg dose)95% CI: -16.15% to -8.68%, random-effects model. |
| Absolute weight loss | 9.8 kg (mean) [azam-2026]95% CI: -13.15 to -6.37 kg. |
| Responder rate (≥10% loss) | Not explicitly reported in available abstracts |
| Mechanism | Appetite suppression (GLP-1) + energy expenditure (glucagon) [elmendorf-2026] |
| BMI reduction | Significant reduction in Chinese adults BMI ≥30 kg/m² [ji-2026] |
| Visceral fat | Expected benefit from glucagon-mediated lipolysis (not quantified in abstracts) |
| Glycemic improvement | HbA1c reduction in T2D cohort (Phase 3 DREAMS-3) |
| Comparator efficacy | Head-to-head vs semaglutide 1 mg (Phase 3 pending publication) [luo-2026] |
| Key publications | Ji et al. Med 2026 · Azam et al. Diab Obes Metab 2026 · Luo et al. Contemp Clin Trials 2026 |
- — Personal or family history of medullary thyroid carcinoma
- — Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- — Hypersensitivity to mazdutide or excipients
- — Pregnancy
- — History of pancreatitis
- — Severe gastroparesis or GI motility disorders
- — Diabetic retinopathy (monitor, risk of worsening with rapid glycemic change)
- — Renal impairment (limited data, use with caution)
- 01Preparation
Supplied as pre-filled pen or reconstituted vial (per manufacturer instructions). Inspect solution — should be clear, colorless to pale yellow. Discard if cloudy or particulate matter present.
- 02Injection site
Subcutaneous — abdomen preferred, also thigh or upper arm. Rotate sites weekly. Avoid areas with scarring, moles, or active inflammation.
- 03Timing
Once weekly, same day each week. May be taken with or without food. If dose missed, administer within 3 days; if >3 days, skip and resume next scheduled dose.
- 04Storage
Refrigerate 2–8 °C. Do not freeze. May be kept at room temperature (<25 °C) for up to 14 days if needed. Protect from light.
- 05Needle technique
Use supplied needle or compatible insulin syringe (if reconstituting). Pinch skin, inject at 90° angle. Hold 5–10 seconds before withdrawing needle to prevent leakage.
Sources
of 62 rendered claims carry a resolvable citation.
- [abdul-2026]Abdul 2026 — Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes.
journal, 2026 - [abulehia-2026]Abulehia 2026 — Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.
journal, 2026 - [azam-2026]Azam 2026 — Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.
journal, 2026 - [elmendorf-2026]Elmendorf 2026 — IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes.
journal, 2026 - [ji-2026]Ji 2026 — Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m(2) but without diabetes: A phase 2 randomized controlled trial.
journal, 2026 - [luo-2026]Luo 2026 — Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial.
journal, 2026